"The Voice of Oncology in Massachusetts"

Contact Us    |      Join    |

FDA Approves AstraZenca & Daiichi Sanyko's Enhertu (trastuzumab deruxtecan) for the Treatment of Adult Patients With Certain Types of Breast Cancer

January 28, 2025 9:26 AM | Katy Monaco

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. Read More.


ADDRESS

860 Winter Street, Waltham, MA, 02451

CONTACT US

tel: 781.434.7316

msco@mms.org

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software